White label – Pompe disease - ClinicalTrials.eu

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Not recruiting

3 1 1
Investigated Drugs:
- Olaparib
+6
Study on [68Ga]Ga-PentixaFor PET Imaging for Identifying Unilateral Adrenal Aldosterone Secretion in Patients with Primary Aldosteronism

Not recruiting

4 1 1
Investigated Drugs:
- Gallium (68Ga)
- Pentixafor
Study of Belimumab for Children with Systemic Lupus Erythematosus (SLE)

Not recruiting

2 1 1 1
Investigated Diseases:
- Systemic lupus erythematosus
Investigated Drugs:
- Belimumab
Study of Olaparib for Patients with Advanced BRCA-Mutated Ovarian Cancer After Initial Platinum-Based Chemotherapy

Not recruiting

3 1 1
Investigated Diseases:
- Ovarian cancer
Investigated Drugs:
- Olaparib
Study on the Effectiveness and Safety of Ocrelizumab for Patients with Progressive Multiple Sclerosis

Not recruiting

3 1 1 1
Investigated Diseases:
- Progressive multiple sclerosis
- Multiple sclerosis
Investigated Drugs:
+1
Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

Not recruiting

3 1 1 1
Investigated Diseases:
- Pneumococcal infection
Investigated Drugs:
Study on the Effectiveness and Safety of Infigratinib for Children Aged 3 to 17 with Achondroplasia

Not recruiting

3 1
Investigated Diseases:
- Osteochondrodysplasia
Investigated Drugs:
- Infigratinib
Study on the Effects of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease and High Protein Levels

Not recruiting

3 1 1 1
Investigated Diseases:
- Chronic kidney disease
Investigated Drugs:
- Zibotentan
- Dapagliflozin
+6
Study on Methoxyflurane for Pain Relief in Adult Dental Emergencies

Not recruiting

3 1 1
Investigated Drugs:
- Methoxyflurane
Study on Skin Care for Patients with Advanced EGFR-Mutated Lung Cancer Treated with Amivantamab and Lazertinib

Not recruiting

2 1 1 1
Investigated Diseases:
- Non-small cell lung cancer
Investigated Drugs:

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies